Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents.

Antigens, Neoplasm Antineoplastic Agents / chemical synthesis Carbonic Anhydrase IX Carbonic Anhydrase Inhibitors / chemical synthesis Carbonic Anhydrases Cell Line, Tumor Cell Proliferation / drug effects Dose-Response Relationship, Drug Drug Development Drug Screening Assays, Antitumor Humans Molecular Structure Structure-Activity Relationship
Carbonic anhydrase inhibitors anticancer agents cancer-related IX and XII isoforms enrichment factor screening funnel

Journal

Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203

Informations de publication

Date de publication:
Dec 2020
Historique:
entrez: 5 8 2020
pubmed: 5 8 2020
medline: 10 4 2021
Statut: ppublish

Résumé

Analysis of the literature data reveals that while inhibition of cancer-related carbonic anhydrase IX and XII isoforms continues to be an important enrichment factor for designing anticancer agent development libraries, exclusive reliance on the

Identifiants

DOI: 10.1080/14756366.2020.1801674 PMID: 32746643 PMC: PMC7470080
pubmed: 32746643
doi: 10.1080/14756366.2020.1801674
pmc: PMC7470080
doi:

Substances chimiques

Antigens, Neoplasm 0
Antineoplastic Agents 0
Carbonic Anhydrase Inhibitors 0
CA9 protein, human EC 4.2.1.1
Carbonic Anhydrase IX EC 4.2.1.1
Carbonic Anhydrases EC 4.2.1.1
carbonic anhydrase XII EC 4.2.1.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1555-1561

Références

Nat Rev Drug Discov. 2006 Sep;5(9):730-9
pubmed: 16888652
J Med Chem. 2015 May 14;58(9):3975-83
pubmed: 25875209
J Enzyme Inhib Med Chem. 2019 Dec;34(1):703-711
pubmed: 30810431
J Enzyme Inhib Med Chem. 2018 Dec;33(1):1137-1149
pubmed: 30001631
Eur J Med Chem. 2019 Oct 1;179:547-556
pubmed: 31276899
Eur J Med Chem. 2019 Nov 1;181:111586
pubmed: 31401537
Bioorg Chem. 2019 Jun;87:838-850
pubmed: 31003041
Metabolites. 2017 Sep 16;7(3):
pubmed: 28926956
J Cell Mol Med. 2010 Apr;14(4):771-94
pubmed: 20015196
Eur J Med Chem. 2017 Oct 20;139:250-262
pubmed: 28802125
Nat Rev Cancer. 2011 Aug 11;11(9):671-7
pubmed: 21833026
Int J Biol Macromol. 2018 Jan;106:840-850
pubmed: 28830777
J Enzyme Inhib Med Chem. 2020 Dec;35(1):506-510
pubmed: 31928252
Bioorg Med Chem. 2014 May 1;22(9):2643-7
pubmed: 24713308
Eur J Med Chem. 2017 May 26;132:184-191
pubmed: 28363153
J Med Chem. 2012 Jun 14;55(11):5591-600
pubmed: 22621623
Gene. 2017 Aug 5;623:33-40
pubmed: 28433659
J Med Chem. 2011 Dec 22;54(24):8271-7
pubmed: 22077347
J Med Chem. 2005 Jul 28;48(15):4834-41
pubmed: 16033263
ACS Med Chem Lett. 2017 Aug 10;8(9):963-968
pubmed: 28947945
Eur J Med Chem. 2020 Mar 1;189:112019
pubmed: 31972394
Biochem J. 2016 Jul 15;473(14):2023-32
pubmed: 27407171
Bioorg Med Chem. 2014 Jul 15;22(14):3684-95
pubmed: 24878360
J Med Chem. 2018 Dec 13;61(23):10860-10874
pubmed: 30433782
Cancer Metastasis Rev. 2019 Jun;38(1-2):65-77
pubmed: 31076951
Molecules. 2018 Apr 30;23(5):
pubmed: 29710858
ACS Med Chem Lett. 2017 Nov 21;8(12):1314-1319
pubmed: 29259754
Nat Chem Biol. 2017 Jun;13(6):675-680
pubmed: 28437394
Expert Opin Ther Pat. 2018 Oct;28(10):709-712
pubmed: 30217119
Eur J Med Chem. 2019 Dec 1;183:111702
pubmed: 31542715
Science. 2017 Apr 28;356(6336):
pubmed: 28302793
Eur J Pharmacol. 2011 Apr 25;657(1-3):173-83
pubmed: 21315712
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4681-5
pubmed: 22721713
PLoS One. 2018 Nov 19;13(11):e0207417
pubmed: 30452451
Br J Cancer. 2003 Apr 7;88(7):1065-70
pubmed: 12671706
Eur J Pharm Sci. 2019 Oct 1;138:105012
pubmed: 31330259
Eur J Med Chem. 2018 Sep 5;157:1214-1222
pubmed: 30193219
Semin Cancer Biol. 2015 Apr;31:52-64
pubmed: 25117006
Bioorg Med Chem. 2015 Jul 1;23(13):3674-80
pubmed: 25921266
Oncol Rep. 2019 Apr;41(4):2585-2594
pubmed: 30720123
Adv Pharmacol. 2012;65:63-107
pubmed: 22959024
Eur J Med Chem. 2020 Mar 15;190:112112
pubmed: 32044580
FEBS Lett. 2004 Nov 19;577(3):439-45
pubmed: 15556624
Chem Biol Interact. 2018 Mar 25;284:12-23
pubmed: 29454615
Nat Rev Drug Discov. 2011 Mar;10(3):197-208
pubmed: 21358739
Nat Rev Drug Discov. 2011 Sep 16;10(10):767-77
pubmed: 21921921
Bioorg Med Chem. 2016 Jul 1;24(13):3043-3051
pubmed: 27234893
Eur J Med Chem. 2014 Jan;71:135-47
pubmed: 24291567
Bioorg Chem. 2020 May;98:103754
pubmed: 32200329
Eur J Med Chem. 2019 Nov 15;182:111600
pubmed: 31419777
Eur J Med Chem. 2019 Jan 15;162:147-160
pubmed: 30445264
Eur J Med Chem. 2019 Feb 15;164:92-105
pubmed: 30594030
Eur J Med Chem. 2020 Feb 15;188:112021
pubmed: 31901743
Bioorg Chem. 2018 Dec;81:425-432
pubmed: 30219719
Eur J Med Chem. 2013 Nov;69:701-10
pubmed: 24095761
Eur J Med Chem. 2018 May 25;152:1-9
pubmed: 29684705
Eur J Med Chem. 2018 Jul 15;155:13-23
pubmed: 29852328
J Enzyme Inhib Med Chem. 2019 Dec;34(1):75-86
pubmed: 30362386
Int J Mol Sci. 2019 Dec 02;20(23):
pubmed: 31810330
J Med Chem. 2016 May 26;59(10):5077-88
pubmed: 27144971
Eur J Med Chem. 2019 Dec 15;184:111768
pubmed: 31629164
Cancer Invest. 2009 Jul;27(6):613-23
pubmed: 19367501
J Med Chem. 2016 Jul 14;59(13):6547-52
pubmed: 27305384
FEBS J. 2016 Jan;283(1):191-200
pubmed: 26470855
Oncotarget. 2018 Jun 1;9(42):26800-26816
pubmed: 29928486
Bioorg Chem. 2019 Nov;92:103222
pubmed: 31499260
Chimia (Aarau). 2017 Oct 25;71(10):643
pubmed: 29070408
Bioorg Chem. 2019 Sep;90:103102
pubmed: 31299596
Cancer Immunol Immunother. 2011 May;60(5):649-58
pubmed: 21298264
Eur J Med Chem. 2019 Apr 15;168:301-314
pubmed: 30826507
Front Cell Dev Biol. 2016 Mar 31;4:27
pubmed: 27066484
Am J Clin Oncol. 2020 Jul;43(7):484-490
pubmed: 32251122
J Enzyme Inhib Med Chem. 2015 Dec;30(6):967-80
pubmed: 25683085
Bioorg Chem. 2018 Apr;77:411-419
pubmed: 29427856

Auteurs

Mikhail Krasavin (M)

Institute of Chemistry, St. Petersburg State University, St. Petersburg, Russia.

Stanislav Kalinin (S)

Institute of Chemistry, St. Petersburg State University, St. Petersburg, Russia.

Tatiana Sharonova (T)

Institute of Chemistry, St. Petersburg State University, St. Petersburg, Russia.

Claudiu T Supuran (CT)

Neurofarba Department, Section of Pharmaceutical Sciences, University of Florence, Florence, Italy.
ORCID: 0000-0003-4262-0323

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes néoplasiques › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes néoplasiques › Carbonic anhydrase IX › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de l'anhydrase carbonique › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Lyases › Carbon-oxygen lyases › Hydro-lyases › Carbonic anhydrases › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de criblage d'agents antitumoraux › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Inhibitory activity against carbonic anhydrase...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Inhibitory activity against carbonic anhydrase...